ARANOTE
11 Apr 2022
ARANATE
NCT04736199
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Bayer
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2021-02-23 |
Anticipated End Date | 2025-09-26 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | Dr Vineet Kwatra |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs